These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26742964)

  • 1. Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer.
    Arikan O; Yýldýrým A; Ýsbilen B; Canakci C; Atýs G; Gurbuz C; Erol B; Ýsman FK; Ozkanli S; Caskurlu T
    Int Braz J Urol; 2015; 41(6):1080-7. PubMed ID: 26742964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
    Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
    BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
    Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
    Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder.
    Latif Z; Watters AD; Dunn I; Grigor KM; Underwood MA; Bartlett JM
    Br J Cancer; 2003 Oct; 89(7):1305-9. PubMed ID: 14520464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
    Lim SD; Cho YM; Choi GS; Park HK; Paick SH; Kim WY; Kim SN; Yoon G
    J Korean Med Sci; 2015 Aug; 30(8):1068-77. PubMed ID: 26240484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
    Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
    BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
    Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
    Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
    Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
    Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
    Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].
    Janane A; Hajji F; Ismail TO; Elondo JC; Ghadouane M; Ameur A; Abbar M; Bouzidi A
    Actas Urol Esp; 2011 Apr; 35(4):189-94. PubMed ID: 21419519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.
    Mangrud OM; Gudlaugsson E; Skaland I; Tasdemir I; Dalen I; van Diermen B; Baak JP; Janssen EA
    Hum Pathol; 2014 Jul; 45(7):1496-503. PubMed ID: 24796506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.